Investor Presentaiton
Initiatives Related to Profit Growth for Current Business and Products
Daiichi-Sankyo
Enhance product portfolio in Japan Business
REYVOW® Migraine treatment
➤ Launched*1 in June 2022
*1 Eli Lilly Japan and Daiichi Sankyo signed an agreement on reverse co-promotion in which
Eli Lilly Japan is responsible for clinical development and manufacturing and Daiichi
Sankyo is in charge of distribution and sales, and the companies will co-promote the
product.
MINEBROⓇ Orally Disintegrating Tablet Antihypertensive agent
➤ Launched in May 2022
片線治療劑 5HT登自体作動開
30PTP (103)
30PTP (10×3)
国産 5-HT
「レイボー錠100mg
(ラスミジテンコハク
- Lilly
0
100mg
「レイボー錠50mg 50円
50mg
イラスミジタンコハク
ミネラルコルチコイド ブロッカー
E7DOD 1.25mg
エサキセレノン
0
1002
100度
ミネラルコルチコイドブロッカー
100
ミネラルコルチコイドブロッカー
ミネブロOD錠2.5mg
ミネブロOD錠5mg
エサキセレノン製剤
エサキセレノン製剤
OD 2.5mg
OD 5mg
MINNEBRO
OD 1.25mg
MINNEBRO
Enhance transformation into a profit structure focused on patented drugs
Concluded an asset sale agreement in Europe
Divested Products: EFIENT ® Antiplatelet agent (FY2021 Revenue: 1.5 Bn JPY)
Date of Agreement: June 2022
New Owner Substipharm
14
14View entire presentation